日本利用iPS细胞治疗小鼠白血病

2010-09-24 MedSci原创 MedSci原创

iPS

  日本北海道大学一个研究小组日前宣布,该小组利用被称为“新万能细胞”的诱导多功能干细胞(iPS细胞),培育出了具有抗肿瘤作用的免疫细胞,然后将其注射到患白血病的小鼠体内,成功使患白血病小鼠的存活期大幅延长。   骨髓移植是白血病的治疗方法之一,在进行骨髓移植时,如果加入骨髓提供者的免疫细胞——T细胞,有时会产生良好效果。北海道大学教授清野一郎等人于是尝试利用骨髓提供者的细胞培育出T细胞。他们把目

  日本北海道大学一个研究小组日前宣布,该小组利用被称为“新万能细胞”的诱导多功能干细胞(iPS细胞),培育出了具有抗肿瘤作用的免疫细胞,然后将其注射到患白血病的小鼠体内,成功使患白血病小鼠的存活期大幅延长。
  骨髓移植是白血病的治疗方法之一,在进行骨髓移植时,如果加入骨髓提供者的免疫细胞——T细胞,有时会产生良好效果。北海道大学教授清野一郎等人于是尝试利用骨髓提供者的细胞培育出T细胞。他们把目光放到了iPS细胞身上。
  iPS细胞之所以被称为“新万能细胞”,是因为它能像胚胎干细胞一样发育成各种细胞。在小鼠试验中,清野一郎等人最终用提供骨髓的小鼠的iPS细胞培育出了它们的T细胞。
  研究人员在给患有白血病的小鼠进行骨髓移植时,通过静脉向这些小鼠注射了这种T细胞。结果发现,在只注射了1次T细胞的7只小鼠中,有1只存活 100天以上;注射两次T细胞的9只小鼠中,则有5只存活100天以上;而只进行了骨髓移植的12只小鼠,则在28天之内全部死亡。
  研究人员认为,这是由于注入的T细胞发挥了抗肿瘤效果。清野一郎指出:“今后准备弄清T细胞的具体功能,从而开发出安全高效的抗肿瘤免疫细胞培育法。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1294104, encodeId=67911294104d5, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377681, encodeId=5c3913e768133, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527098, encodeId=86f5152e0984b, content=<a href='/topic/show?id=24d610019a8' target=_blank style='color:#2F92EE;'>#iPS细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10019, encryptionId=24d610019a8, topicName=iPS细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27a11802753, createdName=wmr115, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1294104, encodeId=67911294104d5, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377681, encodeId=5c3913e768133, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527098, encodeId=86f5152e0984b, content=<a href='/topic/show?id=24d610019a8' target=_blank style='color:#2F92EE;'>#iPS细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10019, encryptionId=24d610019a8, topicName=iPS细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27a11802753, createdName=wmr115, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=)]
    2010-09-26 chengjn
  3. [GetPortalCommentsPageByObjectIdResponse(id=1294104, encodeId=67911294104d5, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377681, encodeId=5c3913e768133, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527098, encodeId=86f5152e0984b, content=<a href='/topic/show?id=24d610019a8' target=_blank style='color:#2F92EE;'>#iPS细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10019, encryptionId=24d610019a8, topicName=iPS细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27a11802753, createdName=wmr115, createdTime=Sun Sep 26 06:48:00 CST 2010, time=2010-09-26, status=1, ipAttribution=)]
    2010-09-26 wmr115